Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in alzheimer's disease: A 3-year follow-up longitudinal study

Journal of Alzheimer's Disease

Volumn 17, Issue 1, 2009, Pages 203-211

  Angelucci, Francesco ^a   Bernardini, Sergio ^b   Gravina, Paolo ^b   Bellincampi, Lorenza ^b   Trequattrini, Alberto ^c   Di Iulio, Fulvia ^a   Vanni, Diego ^a   Federici, Giorgio ^b   Caltagirone, Carlo ^a,b   Boss, Paola ^a   Spalletta, Gianfranco ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c ASL Citt di Castello   (Italy)

Author keywords

5 HT2A receptor; Alzheimer's disease; Antipsychotic drugs; Delusions; Hallucinations

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR;

5 HT2A RECEPTOR GENE; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; DELUSION; DISEASE SEVERITY; DRUG MECHANISM; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; RECEPTOR GENE; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 67650888591     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1031     Document Type: Article

References (35)

1. Ballard C (2007) Agitation and psychosis in dementia. Am J Geriatr Psychiatry 15, 913-917.
2. Lesser JM, Hughes S (2006) Psychosis-related disturbances. Psychosis, agitation, and disinhibition in Alzheimer's disease: definitions and treatment options. Geriatrics 61, 14-20.
3. Wilkosz PA, Miyahara S, Lopez OL, Dekosky ST, Sweet RA (2006) Prediction of psychosis onset in Alzheimer disease: The role of cognitive impairment, depressive symptoms, and further evidence for psychosis subtypes. Am J Geriatr Psychiatry 14, 352-360.
4. Donaldson C, Tarrier N, Burns A (1997) The impact of the symptoms of dementia on caregivers. Br J Psychiatry 170, 62-68.
5. Knopman DS, Berg JD, Thomas R, Grundman M, Thal LJ, Sano M (1999) Nursing home placement is related to dementia progression: experience from a clinical trial. Neurology 52, 714-718.
6. Ballard C, Waite J (2006) The effectiveness of atypical an- tipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 1, CD003476.
7. Forstl H, Burns A, Levy R, Cairns N (1994) Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease. Br J Psychiatry 165, 53-59.
8. Zubenko GS, Moossy J, Martinez AJ, Rao G, Claassen D, Rosen J, Kopp U (1991) Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 48, 619-624.
9. Lucki I (1998) The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44, 151-162.
10. Jann MW. (2004) Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy 24, 1759-1783.
11. Holmes C, Arranz MJ, Powell JF, Collier DA, Lovestone S (1998) 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet 7, 1507-1509.
12. Nacmias B, Tedde A, Forleo P, Piacentini S, Guarnieri BM, Bartoli A, Ortenzi L, Petruzzi C, Serio A, Marcon G, Sor- bi S (2001) Association between 5-HT2A receptor polymorphism and psychotic symptoms in Alzheimer's disease. Biol Psychiatry 50, 472-475.
13. Rocchi A, Micheli D, Ceravolo R, Manca ML, Tognoni G, Siciliano G, Murri L (2003) Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease. Genet Test Winter 7, 309-314.
14. Lam LC, Tang NL, Ma SL, Zhang W, Chiu HF (2004) 5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer's disease, Int J Geriatric Psychiatry 19, 523-526.
15. Holmes C, Arranz M, Collier D, Powell J, Lovestone S (2003) Depression in Alzheimer's disease: the effect of serotonin receptor gene variation. Am J Med Genet B Neuropsychiatr Genet 119, 40-43.
16. Assal F, Alarcon M, Solomon EC, Masterman D, Geschwind DH, Cummings JL (2004) Aug;Association of the serotonin transporter and receptor gene polymorphisms in neuropsychi- atric symptoms in Alzheimer disease. Arch Neurol 61, 1249-1253.
17. Wilkosz PA, Kodavali C, Weamer EA, Miyahara S, Lopez OL, Nimgaonkar VL, Dekosky ST, Sweet RA (2007) Prediction of psychosis onset in Alzheimer disease: The role of depression symptom severity and the HTR2A T102C polymorphism. Am J Med Genet B Neuropsychiatr Genet 144, 1054-1062.
18. Craig D, Donnelly C, Hart D, Carson R, Passmore P. (2007) Analysis of the 5HT-2A T102C receptor polymorphism and psychotic symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 144, 126-128.
19. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R (1995) Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346, 281-282.
20. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH (2002) Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am JPsychi- atry 159, 1593-1595.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
22. Folstein MF, Folstein SE, McHugh PR (1975) Mini Mental State: a practical method for grading the cognitive state of patients for clinician. J Psychiatric Res; 12, 189-198.
23. Cummings JL (2004) Alzheimer's disease. N Engl J Med 351, 56-67.
24. Cummings JL (1997) The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 48, S10-S16.
25. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9, 179-186.
26. Levitan RD, Masellis M, Basile VS, Lam RW, Jain U, Kaplan AS, Kennedy SH, Siegel G, Walker ML, Vaccarino FJ, Kennedy JL (2002) Polymorphism ofthe serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder. J Affect Disord 71, 229-233.
27. Norton N, Owen MJ (2005) HTR2A: association and expression studies in neuropsychiatric genetics. Ann Med 37, 121-129.
28. Khait VD, Huang YY, Zalsman G, Oquendo MA, Brent DA, Harkavy-Friedman JM, Mann JJ (2005) Association of serotonin 5-HT2A receptor binding and the T102C polymorphism in depressed and healthy Caucasian subjects. Neuropsy- chopharmacology 30, 166-172.
29. Polesskaya OO, Sokolov BP (2002) Differential expression of the 'C' and 'T' alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 67, 812-822.
30. Hurlemann R, Matusch A, Kuhn KU, Berning J, Elmenhorst D, Winz O, Kolsch H, Zilles K, Wagner M, Maier W, Bauer A (2008) 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology 195, 579-590.
31. Ito H, Nyberg S, Halldin C, Lundkvist C, Farde L (1998) PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. J Nucl Med39, 208-214.
32. Barnes N, Sharp T (1999) A review ofcentral 5HT receptors and their functions, Neuropharmacology 38, 1083-1152.
33. Fiorella D, Rabin R, Winter J (1995) Role of the 5HT2A and 5HT2C receptors in the stimulus effects ofhallucinogenic drugs. II. Reassessment of LSD false positives, Psychophar-macology 121, 357-363.
34. Leysen JE, Janssen PM, Megens AA, Schotte A (1994) Risperidone: a novel antipsychotic with balanced serotonin- dopamine antagonism, receptor occupancy profile, and phar- macologic activity. J Clin Psychiatry 55, 5-12.
35. Yatham LN, Steiner M, Liddle PF, Shiah IS, Lam RW, Zis AP, Coote M (2000) A PET study of brain 5-HT2 receptors and their correlation with platelet 5-HT2 receptors in healthy humans. Psychopharmacology 151, 424-427.